Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 22 member 5 (SLC22A5), commonly known as OCTN2, is the principal transporter responsible for the renal reabsorption of levocarnitine (L-carnitine) from the glomerular filtrate [1, 17]. Located on the apical membrane of renal proximal tubule cells, it functions as a high-affinity, sodium-dependent symporter that recovers over 95% of filtered carnitine to maintain systemic homeostasis [5, 15]. This process is vital for cellular energy production, as carnitine is required to shuttle long-chain fatty acids into the mitochondria for beta-oxidation [4, 23]. Mutations in the SLC22A5 gene lead to primary systemic carnitine deficiency, a condition characterized by life-threatening cardiomyopathy, skeletal muscle weakness, and hypoketotic hypoglycemia [6, 8]. Beyond its physiological role, OCTN2 acts as a polyspecific transporter for various drugs, including certain antibiotics and chemotherapeutics like etoposide and oxaliplatin [1, 12]. Pharmacological inhibition or downregulation of OCTN2 by drugs such as valproic acid or cisplatin can lead to secondary carnitine deficiency and associated toxicities [7, 10, 13]. Consequently, OCTN2 is a significant factor in drug disposition and a key target for managing metabolic and drug-induced carnitine imbalances [12, 24].
Sodium-dependent high-affinity symport of L-carnitine across the apical membrane of renal proximal tubule cells, coupled with the transport of sodium ions in a 1:1 stoichiometry [5, 8]. It also functions as a sodium-independent organic cation transporter, facilitating the secretion of various xenobiotics [1, 21].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 22 member 5 (OCTN2) (OCTN2).